Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
Monoclonal antibodies are an evolving treatment modality in chronic lymphocytic leukemia that has the potential to provide more effective and safer targeted therapy. This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics.
Zent
Clive S
CS
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. zent.clive@mayo.edu
Kay
Neil E
NE
D000074323:Alemtuzumab; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001327:Autoimmune Diseases / Q000209:etiology; D019468:Disease Management; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D007970:Leukopenia / Q000209:etiology; D051379:Mice; D009363:Neoplasm Proteins / Q000276:immunology; D051381:Rats; D012306:Risk; D000069283:Rituximab; D015275:Tumor Lysis Syndrome / Q000209:etiology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D009363:Neoplasm Proteins; D000074323:Alemtuzumab; D000069283:Rituximab